Image
Interactive Exchange™

How Low Do You Go?

Clinical Updates in LDL-C Management

Meeting Slides

Guidelines

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Stone NJ, et al. Circulation. 2014;129(25 suppl 2):S1-S45.

National Lipid Association Recommendations For Patient-Centered Management Of Dyslipidemia: Part 1-Full Report.

Jacobson TA, et al. J Clin Lipidol. 2015;9(2):129-169.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

Lloyd-Jones DM, et al. J Am Coll Cardiol. 2016;pii:S0735-1097(16)32398-1.

Patient Resources

Centers for Disease Control and Prevention

High cholesterol education materials for patients about high cholesterol.

American Heart Association

Resources on managing hyperlipidemia means controlling cholesterol and triglycerides.

The FH Foundation

A patient-centered nonprofit organization dedicated to education, advocacy, and research on familial hypercholesterolemia (FH).

Clinical Assessment Tools

ASCVD Risk Estimator

A companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk and the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Goff DC, et al. JACC. 2014;633(25):2935-2959).

Reynolds Risk Score

A framework for calculating heart and stroke risk for women and men (Ridker PM, et al. JAMA. 2007;297:611-619).

Risk Assessment Tool for Estimating 10-year Risk of Having a Heart Attack

A tool developed based on the Framingham Heart Study (Wilson PW, et al. Circulation. 1998;97(18):1837-1847).

Suggested Readings

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Goldberg AC, et al. J Clin Lipid. 2011;5(3 Suppl):S1-S8

Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Robinson JG. J Manage Care Pharm. 2013;19(2):139-149. 

Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.

Cohen JD, et al. J Clin Lipidol. 2012;6(3):208-215.

An assessment by the Statin Muscle Safety Task Force: 2014 update.

Rosenson RS, et al. J Clin Lipidol. 2014;8(3Suppl):S58-S71.

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

Stroes E, et al. Am J Cardiol. 2014;63(23):2541-2548.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.

Roth EM, et al. Intern J Cardiol. 2014;176(1):55-61.

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

Koren MJ, et al. J Am Coll Cardiol. 2014;63(23):2531-2540.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Robinson JG, et al. N Engl J Med. 2015;372(16):1489-1499.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Sabatine MS, et al. N Engl J Med. 2015;372(16):1500-1509.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.

Moriarty PM, et al. J Clin Lipid. 2015;9:758-769.

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.

Nissen SE, et al. JAMA. 2016;315(15):1580-1590.

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.

Kastelein JJP, et al. Euro Heart J. 2015;36(43):2996-3003.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Raal FJ, et al. Lancet. 2015;385(9965):331-340.

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

Raal FJ, et al. Lancet. 2015;385(9965):341-350.

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

Bays H, et al. J Clin Endocrinol Metab. 2015;100(8):3140-3148.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, et al. N Engl J Med. 2015;372(25):2387-2397. 

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Bohula EA, et al. Circulation. 2015;132(13):1224-1233. 

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.

Zhang XL, et al. BMC Medicine. 2015;13(123):1-18.

Interactive Presentation

Scientific Insights Into LDL-C, PCSK9, and CV RISKS

James A. Underberg, MD


Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Acute Management of Migraine Attacks

Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Issues in Chronic Pain

Consensus and Controversies for Responsible Opioid Prescribing

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clearing the Air

Improving Outcomes for Patients with COPD

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Improving Outcomes in Non–24-Hour Sleep-Wake Disorder

Identifying Patients and Tailoring Therapy

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Comprehensive Chronic Pain Management

A Focus on Patients With Opioid-Induced Constipation

Clinical Issues in Bipolar Depression

Consensus and Controversies Across the Spectrum of Patient Presentations

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Can You Spot Axial Spondyloarthritis?

The PCP’s Role in Timely Recognition and Referral

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice